TY - JOUR
T1 - Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas
AU - Piludu, Francesca
AU - Marzi, Simona
AU - Pace, Andrea
AU - Villani, Veronica
AU - Fabi, Alessandra
AU - Carapella, Carmine Maria
AU - Terrenato, Irene
AU - Antenucci, Anna
AU - Vidiri, Antonello
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Introduction: The aim of this study is to investigate whether early changes in tumor volume and perfusion measurements derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may predict response to antiangiogenic therapy in recurrent high-grade gliomas. Methods: Twenty-seven patients who received bevacizumab every 3 weeks were enrolled in the study. For each patient, three MRI scans were performed: at baseline, after the first dose, and after the fourth dose of bevacizumab. The entire tumor volume (Vtot), as well as contrast-enhanced and noncontrast-enhanced tumor subvolumes (VCE-T1 and VNON-CE-T1, respectively) were outlined using post-contrast T1-weighted images as a guide for the tumor location. Histogram analysis of normalized IAUGC (nIAUGC) and transfer constant Ktrans maps were performed. Each patient was classified as a responder patient if he/she had a partial response or a stable disease or as a nonresponder patient if he/she had progressive disease. Results: Responding patients showed a larger reduction in VNON-CE-T1 after a single dose, compared to nonresponding patients. Tumor subvolumes with increased values of nIAUGC and Ktrans, after a single dose, significantly differed between responders and nonresponders. The radiological response was found to be significantly associated to the clinical outcome. After a single dose, Vtot was predictive of overall survival (OS), while VCE-T1 showed a tendency of correlation with OS. Conclusion: Tumor subvolumes with increased nIAUGC and Ktrans showed the potential for improving the diagnostic accuracy of DCE. Early assessments of the entire tumor volume, including necrotic areas, may provide complementary information of tumor behavior in response to anti-VEGF therapies and is worth further investigation.
AB - Introduction: The aim of this study is to investigate whether early changes in tumor volume and perfusion measurements derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may predict response to antiangiogenic therapy in recurrent high-grade gliomas. Methods: Twenty-seven patients who received bevacizumab every 3 weeks were enrolled in the study. For each patient, three MRI scans were performed: at baseline, after the first dose, and after the fourth dose of bevacizumab. The entire tumor volume (Vtot), as well as contrast-enhanced and noncontrast-enhanced tumor subvolumes (VCE-T1 and VNON-CE-T1, respectively) were outlined using post-contrast T1-weighted images as a guide for the tumor location. Histogram analysis of normalized IAUGC (nIAUGC) and transfer constant Ktrans maps were performed. Each patient was classified as a responder patient if he/she had a partial response or a stable disease or as a nonresponder patient if he/she had progressive disease. Results: Responding patients showed a larger reduction in VNON-CE-T1 after a single dose, compared to nonresponding patients. Tumor subvolumes with increased values of nIAUGC and Ktrans, after a single dose, significantly differed between responders and nonresponders. The radiological response was found to be significantly associated to the clinical outcome. After a single dose, Vtot was predictive of overall survival (OS), while VCE-T1 showed a tendency of correlation with OS. Conclusion: Tumor subvolumes with increased nIAUGC and Ktrans showed the potential for improving the diagnostic accuracy of DCE. Early assessments of the entire tumor volume, including necrotic areas, may provide complementary information of tumor behavior in response to anti-VEGF therapies and is worth further investigation.
KW - Bevacizumab
KW - DCE MRI
KW - High-grade glioma
KW - Perfusion MRI
KW - Quantitative image analysis
UR - http://www.scopus.com/inward/record.url?scp=84947486439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947486439&partnerID=8YFLogxK
U2 - 10.1007/s00234-015-1582-9
DO - 10.1007/s00234-015-1582-9
M3 - Article
C2 - 26364181
AN - SCOPUS:84947486439
VL - 57
SP - 1269
EP - 1280
JO - Neuroradiology
JF - Neuroradiology
SN - 0028-3940
IS - 12
ER -